FDA – Page 296 – Pharma.Tips

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Addressing Pet Failures During PAI Readiness with Effective CAPA Implementation In pharmaceutical manufacturing, particularly with ophthalmic dosage forms, the readiness for a Pre-Approval Inspection (PAI) is critical. One widespread issue…

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Investigating Packaging Dry-Out Issues during Die-Cutting in Pharmaceutical Manufacturing In the dynamic environment of pharmaceutical manufacturing, particularly in the production of transdermal drug delivery systems, challenges such as packaging dry-out…

Assay Oos after adhesive change: GMP investigation plan and CAPA

Investigation Plan and CAPA for Assay OOS Following Adhesive Change Investigating Out-of-Specification (OOS) assay results after an adhesive change presents a critical challenge in pharmaceutical manufacturing. Such deviations can signify…

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Ivpt Failures in Transdermal Patch Manufacturing In the pharmaceutical industry, ensuring consistent product quality is paramount, especially in the manufacturing of transdermal patches. An…

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Investigating Particulate Matter OOS for Multi-Dose Products: Effective Sampling, Filtration, and Environmental Controls Particulate matter contamination in multi-dose pharmaceutical products, particularly ophthalmic formulations, can pose significant challenges to manufacturers. The…

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

Examining Ccit Failure During Terminal Sterilization: An In-Depth Investigation Narrative Ccit failure during terminal sterilization poses significant challenges within pharmaceutical manufacturing, potentially leading to batch rejections and regulatory scrutiny. Understanding…

Dose Delivery Variability during EU/UK market supply: inspection-ready documentation pack

Dose Delivery Variability Investigation for EU/UK Market Supply: An Organized Approach Variability in dose delivery can significantly impact therapeutic outcomes and regulatory compliance in pharmaceutical manufacturing. In environments such as…

Ph Drift during bulk hold: cleaning validation and worst-case selection

Investigation of pH Drift during Bulk Hold: Cleaning Validation and Worst-Case Selection pH drift during bulk hold presents significant challenges for pharmaceutical manufacturers, particularly within the realm of topical and…

Dose Delivery Variability at accelerated stability: process parameter review and validation impact

Investigation of Dose Delivery Variability During Accelerated Stability Testing In the dynamic environment of pharmaceutical manufacturing, variability in dose delivery during accelerated stability testing can lead to significant quality concerns,…

E&L Failure after packaging change: sampling, filtration, and EM controls

In the highly regulated landscape of pharmaceutical manufacturing, a packaging change can inadvertently lead to Extractables and Leachables (E&L) failures in drug products. Such occurrences pose significant quality risks and…

Curling After Packaging during EU/UK market supply: root cause mapping across materials and process

Root Cause Mapping for Curling in Transdermal Drug Delivery Systems after Packaging The occurrence of curling in transdermal drug delivery systems after packaging can pose significant challenges for pharmaceutical manufacturers,…

Fill Weight Variability after packaging change: GMP investigation and CAPA strategy

Investigation of Fill Weight Variability Following a Packaging Change in Pharmaceutical Manufacturing In pharmaceutical manufacturing, consistency in fill weight is crucial for ensuring product quality and regulatory compliance. Recently, a…